Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments.

Authors:
Peter Connick Madhan Kolappan Rickie Patani Michael A Scott Charles Crawley Xiao-Ling He Karen Richardson Kelly Barber Daniel J Webber Claudia A M Wheeler-Kingshott Daniel J Tozer Rebecca S Samson David L Thomas Ming-Qing Du Shi L Luan Andrew W Michell Daniel R Altmann Alan J Thompson David H Miller Alastair Compston Siddharthan Chandran

Trials 2011 Mar 2;12:62. Epub 2011 Mar 2.

Dept, of Clinical Neurosciences, University of Cambridge, UK.

Background: No treatments are currently available that slow, stop, or reverse disease progression in established multiple sclerosis (MS). The Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) trial tests the safety and feasibility of treatment with a candidate cell-based therapy, and will inform the wider challenge of designing early phase clinical trials to evaluate putative neuroprotective therapies in progressive MS. Illustrated by the MSCIMS trial protocol, we describe a novel methodology based on detailed assessment of the anterior visual pathway as a model of wider disease processes--the "sentinel lesion approach".

Methods/design: MSCIMS is a phase IIA study of autologous mesenchymal stem cells (MSCs) in secondary progressive MS. A pre-test : post-test design is used with healthy controls providing normative data for inter-session variability. Complementary eligibility criteria and outcomes are used to select participants with disease affecting the anterior visual pathway.

Results: Ten participants with MS and eight healthy controls were recruited between October 2008 and March 2009. Mesenchymal stem cells were successfully isolated, expanded and characterised in vitro for all participants in the treatment arm.

Conclusions: In addition to determining the safety and feasibility of the intervention and informing design of future studies to address efficacy, MSCIMS adopts a novel strategy for testing neuroprotective agents in MS--the sentinel lesion approach--serving as proof of principle for its future wider applicability.

Trial Registration: ClinicalTrials.gov (NCT00395200).

Download full-text PDF

Source
http://dx.doi.org/10.1186/1745-6215-12-62DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059276PMC
March 2011

Publication Analysis

Top Keywords

stem cells
16
mesenchymal stem
16
multiple sclerosis
12
mscims trial
12
safety feasibility
8
pre-test post-test
8
healthy controls
8
sclerosis mscims
8
trial protocol
8
anterior visual
8
cells multiple
8
mscims
5
controls providing
4
disease anterior
4
providing normative
4
visual pathwayresults
4
design healthy
4
secondary progressive
4
progressive pre-test
4
post-test design
4

Altmetric Statistics


Show full details
2 Total Shares
1 Facebook Pages
1 Tweets
2 Citations

Similar Publications

Isolation and characterization of mesenchymal stem cells from umbilical cord of giant panda.

Authors:
Yuliang Liu Feiping Li Zhigang Cai Donghui Wang Rong Hou Hao Zhang Ming Zhang Shangmian Yie Kongju Wu Changjun Zeng Junhui An

Tissue Cell 2021 Feb 26;71:101518. Epub 2021 Feb 26.

Chengdu Research Base of Giant Panda Breeding, Chengdu, Sichuan Province, 610000, China; Sichuan Key Laboratory of Conservation Biology for Endangered Wildlife, Chengdu, Sichuan Province, 610000, China. Electronic address:

Umbilical cord-derived mesenchymal stem cells (UC-MSCs) constitute a class of cells with significant self-renewal and multilineage differentiation properties and have great potential for therapeutic applications and the genetic conservation of endangered animals. In this study, we successfully isolated and cultured UC-MSCs from the blood vessels of giant panda umbilical cord (UC). The cells were arranged in a vortex or cluster pattern and exhibited a normal karyotype, showing the morphological characteristics of fibroblasts. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

3D printing of chemical-empowered tendon stem/progenitor cells for functional tissue repair.

Authors:
Yanjie Zhang Tingyun Lei Chenqi Tang Yangwu Chen Youguo Liao Wei Ju Hong Zhang Bo Zhou Renjie Liang Tao Zhang Chunmei Fan Xiaoyi Chen Yanyan Zhao Yuanhao Xie Jinchun Ye Boon Chin Heng Xiao Chen Yi Hong Weiliang Shen Zi Yin

Biomaterials 2021 Feb 15;271:120722. Epub 2021 Feb 15.

Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cells and Regenerative Medicine, Department of Orthopedic Surgery of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China; Key Laboratory of Tissue Engineering and Regenerative Medicine of Zhejiang Province, School of Medicine, Zhejiang University, Hangzhou, China; China Orthopaedic Regenerative Medicine (CORMed), Hangzhou, China. Electronic address:

Tendon injuries are the leading cause of chronic debilitation to patients. Tendon stem/progenitor cells (TSPCs) are potential seed cells for tendon tissue engineering and regeneration, but TSPCs are prone to lose their distinct phenotype in vitro and specific differentiation into the tenocyte lineage is challenging. Utilizing small molecules in an ex vivo culture system may be a promising solution and can significantly improve the therapeutic applications of these cells. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Multiomics analyses of cytokines, genes, miRNA, and regulatory networks in human mesenchymal stem cells expanded in stirred microcarrier-spinner cultures.

Authors:
Alan Tin-Lun Lam Alison P Lee Premkumar Jayaraman Kah Yong Tan Deepak Raghothaman Hsueh Lee Lim He Cheng Lihan Zhou Andy Hee-Meng Tan Shaul Reuveny Steve Oh

Stem Cell Res 2021 Feb 26;53:102272. Epub 2021 Feb 26.

Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Singapore. Electronic address:

Mesenchymal stem cells (MSCs) are of great clinical interest as a form of allogenic therapy due to their excellent regenerative and immunomodulatory effects for various therapeutic indications. Stirred suspension bioreactors using microcarriers (MC) have been used for large-scale production of MSCs compared to planar cultivation systems. Previously, we have demonstrated that expansion of MSCs in MC-spinner cultures improved chondrogenic, osteogenic, and cell migration potentials as compared to monolayer-static cultures. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Npac Is a Co-factor of Histone H3K36me3 and Regulates Transcriptional Elongation in Mouse Embryonic Stem Cells.

Authors:
Sue Yu Jia Li Guanxu Ji Zhen Long Ng Jiamin Siew Wan Ning Lo Ying Ye Yuan Yuan Chew Yun Chau Long Wensheng Zhang Ernesto Guccione Yuin Han Loh Zhi-Hong Jiang Henry Yang Qiang Wu

Genomics Proteomics Bioinformatics 2021 Mar 3. Epub 2021 Mar 3.

Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore; The State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau 999078, China. Electronic address:

Chromatin modification contributes to pluripotency maintenance in embryonic stem cells (ESCs). However, the related mechanisms remain obscure. Here, we show that Npac, a "reader" of histone H3 lysine 36 trimethylation (H3K36me3), is required to maintain mouse ESC (mESC) pluripotency since knockdown of Npac causes mESC differentiation. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Human limbal epithelial stem cell regulation, bioengineering and function.

Authors:
Clemence Bonnet Sheyla Gonzalez JoAnn S Roberts Sarah Robertson Maxime Ruiz Jie Zheng Sophie X Deng

Prog Retin Eye Res 2021 Mar 3:100956. Epub 2021 Mar 3.

Cornea Division, Stein Eye Institute, University of California, Los Angeles, CA, 90095, USA. Electronic address:

The corneal epithelium is continuously renewed by limbal stem/progenitor cells (LSCs), a cell population harbored in a highly regulated niche located at the limbus. Dysfunction and/or loss of LSCs and their niche cause limbal stem cell deficiency (LSCD), a disease that is marked by invasion of conjunctival epithelium into the cornea and results in failure of epithelial wound healing. Corneal opacity, pain, loss of vision, and blindness are the consequences of LSCD. Read More

View Article and Full-Text PDF
March 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap